Aelis Farma SA (AELIS.PA)
EUR 2.18
(2.83%)
EUR 2.18
(2.83%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 13.08 Million EUR | -32.67% |
| 2022 | 19.42 Million EUR | -29.13% |
| 2021 | 27.41 Million EUR | 255.62% |
| 2020 | 7.7 Million EUR | 28.14% |
| 2019 | 6.01 Million EUR | 53.59% |
| 2018 | 3.91 Million EUR | -14.9% |
| 2017 | 4.6 Million EUR | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 10.52 Million EUR | 0.0% |
| 2024 Q1 | 10.52 Million EUR | -19.52% |
| 2023 Q3 | 13.08 Million EUR | -22.08% |
| 2023 FY | 13.08 Million EUR | -32.67% |
| 2023 Q4 | 13.08 Million EUR | 0.0% |
| 2023 Q2 | 16.78 Million EUR | -0.02% |
| 2023 Q1 | 16.78 Million EUR | -13.58% |
| 2022 Q4 | 19.42 Million EUR | 0.01% |
| 2022 Q3 | 19.42 Million EUR | -8.6% |
| 2022 Q2 | 21.25 Million EUR | 0.0% |
| 2022 Q1 | 21.25 Million EUR | -22.47% |
| 2022 FY | 19.42 Million EUR | -29.13% |
| 2021 FY | 27.41 Million EUR | 255.62% |
| 2021 Q2 | 27.93 Million EUR | 0.0% |
| 2021 Q3 | 27.41 Million EUR | -1.87% |
| 2021 Q4 | 27.41 Million EUR | 0.0% |
| 2021 Q1 | 27.93 Million EUR | 262.39% |
| 2020 Q1 | - EUR | 0.0% |
| 2020 Q4 | 7.7 Million EUR | 0.01% |
| 2020 Q3 | 7.7 Million EUR | 0.0% |
| 2020 FY | 7.7 Million EUR | 28.14% |
| 2019 FY | 6.01 Million EUR | 53.59% |
| 2018 FY | 3.91 Million EUR | -14.9% |
| 2017 FY | 4.6 Million EUR | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| ABIONYX Pharma SA | 6.91 Million EUR | -89.236% |
| ABIVAX Société Anonyme | 131.05 Million EUR | 90.019% |
| Adocia SA | 31.87 Million EUR | 58.958% |
| Biophytis S.A. | 15.84 Million EUR | 17.471% |
| Advicenne S.A. | 24.37 Million EUR | 46.343% |
| genOway Société anonyme | 14.45 Million EUR | 9.541% |
| IntegraGen SA | 5.97 Million EUR | -118.737% |
| Medesis Pharma S.A. | 6.42 Million EUR | -103.542% |
| Neovacs S.A. | 3.71 Million EUR | -252.359% |
| NFL Biosciences SA | 3.62 Million EUR | -261.258% |
| Plant Advanced Technologies SA | 6.78 Million EUR | -92.853% |
| Quantum Genomics Société Anonyme | 3.31 Million EUR | -295.153% |
| Sensorion SA | 13.22 Million EUR | 1.113% |
| Theranexus Société Anonyme | 5.01 Million EUR | -160.756% |
| TME Pharma N.V. | 2.78 Million EUR | -369.659% |
| Valbiotis SA | 13.7 Million EUR | 4.581% |
| TheraVet SA | 1.48 Million EUR | -780.812% |
| Valerio Therapeutics Société anonyme | 20.46 Million EUR | 36.095% |
| argenx SE | 402.79 Million EUR | 96.753% |
| BioSenic S.A. | 32.26 Million EUR | 59.459% |
| Celyad Oncology SA | 9.97 Million EUR | -31.088% |
| DBV Technologies S.A. | 38.74 Million USD | 66.241% |
| Galapagos NV | 1.56 Billion EUR | 99.163% |
| Genfit S.A. | 105.92 Million EUR | 87.651% |
| GeNeuro SA | 20.13 Million EUR | 35.054% |
| Hyloris Pharmaceuticals SA | 8.61 Million EUR | -51.881% |
| Innate Pharma S.A. | 132.29 Million EUR | 90.113% |
| Inventiva S.A. | 101.59 Million EUR | 87.125% |
| MaaT Pharma SA | 22.46 Million EUR | 41.776% |
| MedinCell S.A. | 77.77 Million EUR | 83.181% |
| Nanobiotix S.A. | 95.74 Million EUR | 86.338% |
| Onward Medical N.V. | 25.69 Million EUR | 49.101% |
| Oryzon Genomics S.A. | 25.12 Million EUR | 47.941% |
| OSE Immunotherapeutics SA | 59.07 Million EUR | 77.86% |
| Oxurion NV | 19.73 Million EUR | 33.725% |
| Pharming Group N.V. | 228.28 Million EUR | 94.27% |
| Poxel S.A. | 53.9 Million EUR | 75.733% |
| GenSight Biologics S.A. | 34.72 Million EUR | 62.335% |
| Transgene SA | 26.51 Million EUR | 50.673% |
| Financière de Tubize SA | 123.65 Million EUR | 89.422% |
| UCB SA | 6.56 Billion EUR | 99.801% |
| Valneva SE | 341.14 Million EUR | 96.166% |
| Vivoryon Therapeutics N.V. | 4.54 Million EUR | -187.662% |